Forbion Growth Opportunities Fund III Cooperatief U.A., 10% Owner at Braveheart Bio, Inc. (BRVE), bought 3,600,000 shares at $18.00 ($64.8M) on 2026-08-07, disclosed to the SEC on 2026-08-07.
Forbion Growth Opportunities Fund III Cooperatief U.A. purchased 1.92 million shares of Braveheart Bio at $18.00, representing the largest insider purchase in the company's history. This significant capital commitment by a major shareholder suggests strong conviction in the company's pipeline and recent market positioning.
The stock is currently trading at $31.82, representing a 10.68% premium to its 52-week low of $28.75, though it is currently flat against its 52-week high of $31.82.
1) Q3 earnings on 2026-11-05 (based on next_earnings_date); 2) Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO on 2026-08-11 (based on recent_news_7d); 3) The company filed a large shelf registration to provide flexibility for future capital raises following its IPO on 2026-08-11 (based on recent_news_7d).
The stock is currently trading at its 52-week high of $31.82, leaving little room for error if the market corrects following the recent IPO and index inclusion.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.00 | 1,680,000 | $30.2M | 46.7% |
| 2 | $18.00 | 1,920,000 | $34.6M | 53.3% |
| Total | $18.00 avg | 3,600,000 | $64.8M | 100% |